









Mercado
/
Acciones
/
nasdaq-atxs
/

Astria Therapeutics Inc

ATXS

12.510USD

+0.080+0.64%

Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min

705.99MCap. mercado

PérdidaP/E TTM



Astria Therapeutics Inc

12.510

+0.080+0.64%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Astria Therapeutics Inc Compañía

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Información de Astria Therapeutics Inc



Símbolo de cotizaciónATXS

Nombre de la empresaAstria Therapeutics Inc

Fecha de salida a bolsaJun 25, 2015

Director ejecutivoDr. Jill C. Milne, Ph.D.

Número de empleados78

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 25

Dirección22 Boston Wharf Road

CiudadBOSTON

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal02210

Teléfono16173491971

Sitio Webhttps://astriatx.com/

Símbolo de cotizaciónATXS

Fecha de salida a bolsaJun 25, 2015

Director ejecutivoDr. Jill C. Milne, Ph.D.

Ejecutivos de Astria Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Jonathan Violin, Ph.D.

Independent Director

263.32K

Mr. Noah Clauser

Chief Financial Officer

Ms. Elizabeth Higgins

Investor Relations

Dr. Joanne T. Beck, Ph.D.

Independent Director

Dr. Jill C. Milne, Ph.D.

President, Chief Executive Officer, Co-Founder, Director

Mr. Gregg A. Lapointe, CPA

Independent Director

Mr. Andrew Komjathy

Chief Commercial Officer

Dr. Sunil Agarwal, M.D.

Independent Director

Mr. Benjamin Scott Harshbarger

Chief Legal Officer

Ms. Andrea Matthews

Chief Business Officer

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Jonathan Violin, Ph.D.

Independent Director

263.32K

Mr. Noah Clauser

Chief Financial Officer

Ms. Elizabeth Higgins

Investor Relations

Dr. Joanne T. Beck, Ph.D.

Independent Director

Dr. Jill C. Milne, Ph.D.

President, Chief Executive Officer, Co-Founder, Director

Mr. Gregg A. Lapointe, CPA

Independent Director

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: dom., 26 de oct

Accionistas

Tipos de accionistas

Accionistas

Proporción

Perceptive Advisors LLC

11.49%

Vestal Point Capital, LP

8.01%

Forbion Capital Partners

7.28%

Fidelity Management & Research Company LLC

6.48%

Magnetar Capital Partners LP

5.87%

Otro

60.87%

Accionistas

Proporción

Perceptive Advisors LLC

11.49%

Vestal Point Capital, LP

8.01%

Forbion Capital Partners

7.28%

Fidelity Management & Research Company LLC

6.48%

Magnetar Capital Partners LP

5.87%

Otro

60.87%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

31.18%

Investment Advisor/Hedge Fund

22.93%

Venture Capital

15.69%

Private Equity

11.49%

Hedge Fund

11.30%

Research Firm

4.23%

Individual Investor

0.49%

Pension Fund

0.17%

Bank and Trust

0.09%

Otro

2.43%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

263

57.85M

102.50%

-13.18M

2025Q2

263

60.10M

106.50%

-10.94M

2025Q1

281

59.08M

104.77%

-12.46M

2024Q4

268

59.35M

105.17%

-9.44M

2024Q3

247

57.14M

101.27%

-10.09M

2024Q2

228

56.25M

102.41%

-8.30M

2024Q1

210

58.30M

106.65%

+7.30M

2023Q4

179

37.20M

102.69%

+9.26M

2023Q3

171

23.97M

88.11%

-4.33M

2023Q2

175

25.83M

94.82%

-888.95K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Perceptive Advisors LLC

6.49M

11.49%

Jun 30, 2025

Vestal Point Capital, LP

4.52M

8.01%

+342.00K

+8.18%

Jun 30, 2025

Forbion Capital Partners

4.11M

7.28%

+285.00K

+7.46%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.66M

6.48%

-1.15M

-23.93%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.18M

5.64%

-222.43K

-6.53%

Jun 30, 2025

Fidelity Institutional Asset Management

2.80M

4.97%

+671.87K

+31.52%

Jun 30, 2025

TCG Crossover Management, LLC

2.76M

4.89%

Jun 30, 2025

The Vanguard Group, Inc.

2.52M

4.47%

-116.58K

-4.41%

Jun 30, 2025

VR Adviser, LLC

2.46M

4.35%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

Virtus LifeSci Biotech Clinical Trials ETF

0.94%

ALPS Medical Breakthroughs ETF

0.24%

AltShares Merger Arbitrage ETF

0.09%

iShares Micro-Cap ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.04%

Invesco Nasdaq Biotechnology ETF

0.04%

iShares Biotechnology ETF

0.03%

Avantis US Small Cap Equity ETF

0.03%

iShares Russell 2000 Value ETF

0.02%

iShares Russell 2000 ETF

0.01%

Virtus LifeSci Biotech Clinical Trials ETF

Proporción0.94%

ALPS Medical Breakthroughs ETF

Proporción0.24%

AltShares Merger Arbitrage ETF

Proporción0.09%

iShares Micro-Cap ETF

Proporción0.05%

ProShares Ultra Nasdaq Biotechnology

Proporción0.04%

Invesco Nasdaq Biotechnology ETF

Proporción0.04%

iShares Biotechnology ETF

Proporción0.03%

Avantis US Small Cap Equity ETF

Proporción0.03%

iShares Russell 2000 Value ETF

Proporción0.02%

iShares Russell 2000 ETF

Proporción0.01%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Aug 19, 2021

Merger

6→1

Aug 19, 2021

Merger

6→1

Aug 19, 2021

Merger

6→1

Aug 19, 2021

Merger

6→1

Fecha

Tipo

Relación

Aug 19, 2021

Merger

6→1

Aug 19, 2021

Merger

6→1

Aug 19, 2021

Merger

6→1

Aug 19, 2021

Merger

6→1

KeyAI

